Hepatic steatosis tied to vulnerable coronary plaque, higher cardiac risk
-
June 9
CT imaging from the PROMISE trial links hepatic steatosis to lipid-rich plaque and a roughly 1.7-fold higher rate of major adverse cardiovascular events, independent of standard risk factors.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, describe characteristic cyst findings on cross-sectional and endoscopic sonographic imaging, fluid analysis results, and management.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Hepatic steatosis tied to vulnerable coronary plaque, higher cardiac risk
-
by Doug Brunk
CT imaging from the PROMISE trial links hepatic steatosis to lipid-rich plaque and a roughly 1.7-fold higher rate of major adverse cardiovascular events, independent of standard risk factors.
How do advanced IBD therapies compare for serious infection risk?
-
by Julia Cipriano
Across five drug classes for inflammatory bowel disease, concomitant corticosteroids doubled the serious infection risk, regardless of which therapy they accompanied.
How to explain IBS so patients believe you
-
by Bob Alaburda
Faculty shared the language, framing, and prescribing pearls they use to diagnose and counsel patients with disorders of gut-brain interaction.
Long-term dupilumab associated with sustained remission in refractory eosinophilic esophagitis
-
by Olivia Anderson
Real-world 72-week study shows sustained clinical, endoscopic, and histologic improvement in disease activity.
MASH label expansion adds few new semaglutide candidates
-
by Doug Brunk
Most patients with fibrotic liver disease already qualify through obesity- or diabetes-related indications, a population-based analysis found.
